Onyx Biotec Ltd
Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry
Syrup for India and overseas, through a
B2B business model[1]
- Market Cap ₹ 61.3 Cr.
- Current Price ₹ 33.8
- High / Low ₹ 56.0 / 28.1
- Stock P/E
- Book Value ₹ 30.6
- Dividend Yield 0.00 %
- ROCE 1.14 %
- ROE -0.38 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.11 times its book value
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of 6.49% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 44.86 | 39.49 | 53.75 | 61.95 | 69.47 | |
| 39.09 | 34.99 | 45.36 | 51.57 | 66.07 | |
| Operating Profit | 5.77 | 4.50 | 8.39 | 10.38 | 3.40 |
| OPM % | 12.86% | 11.40% | 15.61% | 16.76% | 4.89% |
| 0.12 | 0.11 | 0.13 | 1.17 | 0.44 | |
| Interest | 0.65 | 0.57 | 2.16 | 2.02 | 1.21 |
| Depreciation | 1.45 | 1.49 | 1.87 | 3.05 | 3.05 |
| Profit before tax | 3.79 | 2.55 | 4.49 | 6.48 | -0.42 |
| Tax % | 11.61% | 27.45% | 19.15% | 23.46% | -50.00% |
| 3.35 | 1.84 | 3.63 | 4.95 | -0.21 | |
| EPS in Rs | 5.68 | 3.12 | 2.72 | 2.73 | -0.12 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 21% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -105% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -35% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 6% |
| Last Year: | 0% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 5.90 | 5.90 | 13.32 | 18.13 | 18.13 |
| Reserves | 10.47 | 12.30 | 11.97 | 37.49 | 37.28 |
| 12.25 | 29.23 | 30.78 | 12.46 | 15.17 | |
| 8.22 | 11.30 | 18.07 | 23.17 | 24.57 | |
| Total Liabilities | 36.84 | 58.73 | 74.14 | 91.25 | 95.15 |
| 17.23 | 42.50 | 43.48 | 40.90 | 39.16 | |
| CWIP | 4.02 | 0.00 | 0.00 | 0.00 | 3.68 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 15.59 | 16.23 | 30.66 | 50.35 | 52.31 | |
| Total Assets | 36.84 | 58.73 | 74.14 | 91.25 | 95.15 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 0.49 | 1.96 | 1.52 | 1.42 | -1.49 | |
| -5.78 | -22.68 | -3.15 | 0.66 | -4.58 | |
| 5.20 | 16.43 | 3.09 | 5.07 | 1.50 | |
| Net Cash Flow | -0.09 | -4.30 | 1.46 | 7.15 | -4.57 |
| Free Cash Flow | -5.30 | -20.78 | -1.70 | 1.91 | -6.48 |
| CFO/OP | 8% | 44% | 18% | 14% | -44% |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 68.51 | 46.95 | 104.37 | 119.19 | 144.49 |
| Inventory Days | 41.98 | 109.92 | 92.94 | 150.14 | 99.20 |
| Days Payable | 59.46 | 120.16 | 140.83 | 156.02 | 124.70 |
| Cash Conversion Cycle | 51.03 | 36.71 | 56.48 | 113.32 | 118.98 |
| Working Capital Days | 35.72 | -52.22 | 37.62 | 87.49 | 77.29 |
| ROCE % | 8.23% | 12.85% | 12.16% | 1.14% |
Insights
In beta| Mar 2010 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Number of Principal Manufacturing Units units |
|
|||
| Number of Production Machines - Unit I (Sterile Water for Injections) units |
||||
| Debtors Turnover Ratio times |
||||
| Total Permanent Employees count |
||||
| Year-on-Year Employee Value/Growth (Industry Job Listing Benchmark) % |
||||
Extracted by Screener AI
Documents
Announcements
-
Statement of deviation(s) or variation(s) under Reg. 32
14 May 2026 - No deviation in IPO fund use for half year ended 31 March 2026; net proceeds Rs. 2,538.02 lakh.
-
Outcome of Board Meeting
14 May 2026 - FY26 audited results: revenue Rs 6,991.40 lakh, net profit Rs 68.60 lakh; auditors gave unmodified opinion.
-
Structural Digital Database
7 May 2026 - Compliance certificate confirms Structured Digital Database for FY2026; 3 events captured, no noncompliance.
-
Reply to Clarification- Financial results
22 April 2026 - Onyx Biotec submits auditor certificate for IPO proceeds utilization as of September 30, 2025; no deviation.
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
7 April 2026 - Onyx Biotec says corporate governance provisions are not applicable for quarter ended March 31, 2026.
Business Overview:[1]
OBL is associated with the healthcare segment and is a supplier of sterile pharmaceutical products to major corporations. Presently, OBL manufactures Sterile Water for Injections, and acts as a pharmaceutical contract manufacturer offering a comprehensive range of Dry Powder Injections and Dry Syrup for India and overseas. It provides end-to-end product development and manufacturing solutions and its services
also include preparation and filing of regulatory dossiers in the Indian and global markets.